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See Article, pages 792–798In this issue, the Journal of Hepatology is publishing a non-infe-
riority trial by a Korean group on severe alcoholic hepatitis
addressing the question of the efﬁcacy of pentoxifylline and cor-
ticosteroids. Although several studies have been performed in
this ﬁeld, this subject remains controversial. The European Asso-
ciation for the Study of the Liver (EASL) and the American Asso-
ciation for the Study of Liver Diseases (AASLD) have published
guidelines [1,2] stating that pentoxifylline and corticosteroids
are effective in decreasing mortality in severe alcoholic hepatitis.
Studies have shown that the efﬁcacy of pentoxifylline is due to a
reduction of the incidence of hepatorenal syndrome [3]. Several
papers including meta-analyses [4,5] have reported a beneﬁt in
survival in randomized patients treated with a 28-day course of
corticosteroids. Nevertheless, regardless of the molecule, 6-
month mortality rate remains high, around 30–40% [4]. Very
few studies have compared pentoxifylline and corticosteroids
with a sufﬁciently large population, and it is difﬁcult to deﬁnitely
conﬁrm that one drug is better than the other.
Some clinicians are still reluctant to use corticosteroids
because of the risk of infection. However, decompensated cirrho-
sis per se is associated with a marked risk of infection, mainly
because of liver impairment [6]. In the speciﬁc ﬁeld of severe
alcoholic hepatitis, our group has observed that up to 25% of
patients are admitted with active sepsis, which strongly suggests
that systematic screening for infection should be performed in
these patients. Another 25% will develop infection after cortico-
steroid treatment has begun, mainly in case of non-response to
this drug, supporting the strong link between liver impairment
and the incidence of infection [7]. This latter result is not in
favour of a direct relationship between increased infection and
the use of corticosteroids. An early assessment by the Lille model
can help clinicians tailor therapeutic management according to
the predicted risk of complications, including the risk of infection
[8]. For example, in patients with a Lille model above 0.56, we
strongly recommend withdrawing corticosteroids due to the lack
of beneﬁt of this drug in this subgroup [4].
The study by Park et al. published in this issue of the Journal of
Hepatology reports their work in 124 patients with severeJournal of Hepatology 20
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Open access under CC BY-NC-ND license.alcoholic hepatitis. Patients were randomized to receive pentox-
ifylline or prednisolone according to conventional doses recom-
mended in this ﬁeld (1200 mg/day and 40 mg/day respectively).
Survival was 64.5% in the pentoxifylline-treated group and
72.9% in the prednisolone group. These results are close to those
in patients with severe alcoholic hepatitis published by other
groups. Complications were low with no signiﬁcant differences
between the two groups. Response to treatment assessed by
the Lille model [8] adequately predicted outcome in both
groups. This conﬁrms the prognostic value of the Lille model
for predicting outcome in these two randomized groups. The lat-
ter result emphasizes the importance of early improvement in
liver function to improve survival.
In the study design of this paper, results with pentoxifylline
were not statistically equivalent to prednisolone and the authors
concluded that corticosteroids were better than pentoxifylline for
severe alcoholic hepatitis. The disappointing survival with pen-
toxifylline compared to prednisolone was also suggested by a
recent randomized controlled trial showing a lack of beneﬁt of
the association of pentoxifylline with prednisolone compared to
prednisolone alone [9].
Six-month survival was the primary endpoint of this trial, as
well as of previous trials in the ﬁeld [10–12]. However, in the Cor-
pentox study, a decrease in the incidence of hepatorenal syn-
drome was suggested although the sample size was not
calculated to address this issue. Because many studies have had
interesting results but did not show an improvement in 6-month
survival in severe alcoholic hepatitis [9,12], an international con-
sensus is needed to deﬁne new endpoints. This would help clini-
cians modify the design of future trials so that rather than short-
term survival, other surrogates markers predicting survival
would be the primary endpoint such as improvement in liver fail-
ure and/or the reduction of the incidence of severe complications
leading to death.
Although this study was well designed with a sufﬁcient sam-
ple size, it comports some limitations, which were acknowledged
and discussed by the authors. An important limitation was the
absence of a histological diagnosis of alcoholic hepatitis. This
issue is crucial in severe alcoholic hepatitis because there are
no clinical or biological features to deﬁnitely establish the
diagnosis. For example, in a recent work [13], only 63% of
patients admitted with acute-on-chronic deterioration of alco-
holic cirrhosis had satellitosis deﬁned by a neutrophil inﬁltration14 vol. 61 j 723–724
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surrounding injured hepatocytes. This shows that all patients
with cirrhosis admitted with jaundice who continue drinking
should not be automatically considered as having alcoholic hepa-
titis. In a similar vein, EASL guidelines have stated that clinical
trials evaluating new strategies in severe alcoholic hepatitis
should be based on histological conﬁrmation of the diagnosis
[1]. The controversy on the prerequisite of liver biopsy for studies
testing molecules emphasizes the urgent need for an expert con-
sensus to establish the optimal design for future therapeutic
studies in patients with severe alcoholic hepatitis.
In summary, although this study has some limitations, the
work by Park is an important step in this setting because of the
quality of the design, the sufﬁcient sample size and the quality
of the data. It reports that results with pentoxifylline were not
statistically equivalent to those of prednisolone. It supports that
corticosteroids may be considered ﬁrst-line therapy for severe
alcoholic hepatitis, although this is still being actively debated
by experts in this ﬁeld.
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